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ABSTRACT 
 
Objectives 
To explore the impact on daily life of symptoms experienced by those with systemic 
autoimmunity associated with rheumatoid arthritis (RA).   
 
Methods 
Fifteen people took part in focus groups to explore the impact of symptoms on daily life.  
 
Results 
Core themes included: 1) physical impact of limited hand function and mobility; 2) 
psychological distress experienced included a fear of symptoms progressing into RA, 
uncertainty about the future, feelings of despair, shame and frustration.  
 
Conclusion 
People with arthralgia at risk of developing RA experienced considerable physical and 
psychological impact of symptoms. Greater consideration should be given to the needs of 
people at risk of developing RA.  
4 
 
INTRODUCTION 
Rheumatoid arthritis (RA) is a chronic inflammatory joint disease that causes pain and 
functional impairment, which has a large impact on daily lives. Early identification and 
treatment improves prognosis.(van der Linden et al. 2010) To be able to identify people 
who will develop RA in the future, the EULAR study group for risk factors of RA 
recommended identification and assessment of symptoms in those with arthralgia and 
during the earliest phases of clinical arthritis as a research priority.(Gerlag et al. 2012) 
We have recently described the breadth of symptoms that persons at risk of RA might 
experience in the symptomatic at-risk phase.(Stack et al. 2014) Knowledge of these 
symptoms can facilitate the development of prediction tools and outcome measurement 
in arthralgia, ultimately leading to better prediction of who will develop RA.(van de Stadt 
et al. 2013) However, the early identification of those at risk, means that people are 
subject to investigations earlier, and have greater awareness of their at risk status. 
Research has shown the disease burden experienced by people with arthralgia is 
comparable to the burden experienced by people with established RA.(Kuijper et al. 
2014) Furthermore, people in the earliest phases of disease may have healthcare needs 
that need to be addressed while being monitored (either as part of a research cohort, or 
in a routine healthcare setting). A recent report by Dures et al highlights the gap 
between the need for psychological support in early RA patients and the provision of 
support by rheumatology clinicians and GPs.(Dures et al. 2014a;Dures et al. 2014b)   
The impact of early and established RA on a patient’s daily life is well 
researched,(Bacconnier et al. 2015;Bernatsky et al. 2010;Bury 1982;Gossec et al. 
2011;Shaul 1997) but the impact and consequences of symptoms among people with 
increased risk of RA prior to the onset of synovial swelling have never been described by 
qualitative research.  We describe the impact of symptoms on daily life of people at 
increased risk of RA. 
 
METHODS 
This report extends earlier explorations from a qualitative study on people at risk of RA 
and in patients with early RA to identify symptom complexes.(Stack, van Tuyl, Sloots, 
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van de Stadt, Hoogland, Maat, Mallen, Tiwana, Raza, & van Schaardenburg 2014) Ethical 
approval for this study was obtained from Slotervaart ethical committee.  
Participants were recruited from an ongoing prospective cohort of the Jan van Breemen 
Research Institute | Reade in Amsterdam, The Netherlands that included 487 anti-CCP 
antibody positive individuals with musculoskeletal symptoms who had been referred to a 
rheumatologist. A total of 119 people were contacted by letter and invited to participate 
in one of three focus group discussions. All participants gave signed informed consent. 
Conduct of the discussions has been described in great detail elsewhere.[3] A semi-
structured interview guide was used, specifically asking: ‘How do these symptoms affect 
your daily life? In which situations are these symptoms bothering you the most?’ The 
interview guide was developed by LvT and RS through literature review and discussions 
with patient research partners (WH and BM) The group discussions took place at the Jan 
van Breemen Research Institute/Reade and were moderated by LvT.  
Data were collected until saturation on the primary outcome (perceived symptoms) was 
reached and no new themes emerged. Focus group discussions lasted approximately 60 
to 90 minutes and were analysed according to the inductive thematic analysis method to 
identify core themes in the qualitative data which explored the impact of arthralgia on 
daily living.(Stack, van Tuyl, Sloots, van de Stadt, Hoogland, Maat, Mallen, Tiwana, Raza, 
& van Schaardenburg 2014) The transcripts where analysed by two independent 
researchers (LvT, MS) and one patient research partner (BM) who systematically 
searched for themes in the first group, forged connections between themes, then moved 
on to the next group. After all transcripts were analysed, the two independent 
researchers and the patient research partner compared their results. Differences were 
discussed until consensus was reached and both researchers agreed to the same set of 
major themes. Further data exploration created new categories, which were grouped in 
the themes. Coding was facilitated using NVivo software for qualitative data analysis. 
 
RESULTS 
A total of 15 individuals participated in one of three focus group discussions with two 
focus groups involving 4 participants and one  involving  7. Participants were 11 females 
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and 4 males , mean age 54 years with a mean duration from symptom onset of 12 
months; two used NSAIDs plus hydroxychloroquine, five used NSAIDs only and the 
remaining eight did not use any drugs for arthralgia(Table 1). 
 
To get a better understanding of the group of 15 participants as compared to the entire 
cohort of 487 participants, we compared the distribution of tender joint counts (in 53 
joints), pain score (VAS scale from 0 to 100) and duration of complaints, all at cohort 
entry. While the focus group participants had a significantly higher tender joint count at 
cohort entry compared to the rest of the cohort (median 11 vs 4), both pain score and 
symptom duration were highly similar (VAS 32 vs VAS 35; 12 months vs 12 months). 
 
This paper is focused on impact of symptoms on daily living, therefore, the themes 
extracted explored the physical impact and psychological impact of symptoms. Quotes 
supporting the themes are presented in Table 2, with physical impact quotes coded 
Ph1.1 to Ph1.7 and psychological impact quotes coded as Psy2.1 to Psy6.1, with 2 to 6 
referring to different subthemes of psychological impact. When quotes are part of a 
conversation, the different participants are referred to as A, B or C, and the moderator as 
‘Mod’.  
Physical impact 
Participants described symptoms which led to a decrease in physical functioning and 
decreased participation in everyday activities. Activities such as dressing, washing, eating 
and household chores were impaired. Participants particularly described having problems 
with hand function (Ph1.1 – 1.4) and a decreased mobility (Ph1.5 – 1.6).  
The impact of physical symptoms could be so severe, that participants described the 
psychological distress that physical symptoms had caused as reflected in quote Ph1.7. 
 
Psychological impact 
There was a general feeling of fear and uncertainty amongst the participants when 
describing their symptoms, as they did not know if they were at the beginning of 
something worse to come (i.e. RA). Several participants described the fear of future 
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development of RA as the worst part of their condition (Psy2.1 – 2.3) which was closely 
linked to the described uncertainty about the progression of symptoms to RA in the 
future, influencing participants’ decisions in life and making them feel limited (Psy3.1 – 
3.5). Other described emotions included feelings of shame (Psy4.1), frustration (Psy5.1) 
and despair (Psy6.1). 
 
 
DISCUSSION 
The disruptive impact of RA on a patient’s life is increasingly documented, but the impact 
of symptoms among people at risk of RA has never been described. Here we report on 
the impact of symptoms on the daily lives of anti-CCP antibody positive individuals at risk of 
developing RA. While the physical impact of symptoms was expected, the severity and 
complexity of the psychological impact of early symptoms was remarkable. Psychological 
distress in the form of fear, uncertainty, shame, frustration and despair in those at risk 
dominated the group discussions. Physicians and researchers need to realize the impact 
of musculoskeletal symptoms on the daily lives of anti-CCP antibody positive individuals, 
especially since these people may not have access to services offered to those with a 
confirmed diagnosis and cannot be treated with drugs with proven efficacy.    
 
The participants that joined the discussions are part of the Reade arthralgia cohort. They 
are aware of their increased risk of RA and are voluntarily visiting the rheumatology clinic 
on a yearly basis to monitor their risk. This subgroup of people that volunteered to join a 
focus group discussion on perceived symptoms may differ from the larger cohort.  
The high tender joint count among focus group participants might imply an increased 
psychological impact of the symptoms in this selected group as compared to the rest of 
the cohort. Alternatively, comorbid conditions might have influenced the perceived 
physical or psychological impact of symptoms. Further exploratory investigations are 
needed to fully understand the needs in subgroups of people at increased risk of RA. 
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Nevertheless, the described impact of musculoskeletal symptoms in anti-CCP antibody 
positive individuals on everyday life is substantial and should not be neglected. 
 
It is important to understand where the psychological distress among these anti-CCP 
antibody positive individuals comes from in order to provide help. If making people aware 
of their increased risk of RA induces psychological distress, we might need to provide 
people with resources to deal with this information. About 35% of patients in our at-risk 
cohort go on to develop RA.[5] For this selected group, it is beneficial to be identified and 
treated as early as possible. But for the remaining 65% that never continue to develop 
RA, the benefit/risk ratio will be negative and the figurative ‘sword of Damocles’ might 
induce a complex spectrum of psychological distress. Like the patients that go on to 
develop RA, these people might benefit from psychological services and support, as well 
as from treatment directed at pain or other perceived symptoms.  
  
Although focus group discussions were continued until saturation was reached, the 
primary purpose of the discussions was to investigate the symptoms that people with 
arthralgia experience, not the impact of symptoms. The impact of symptoms on daily life 
unexpectedly dominated the discussions. More in-depth research is needed to investigate 
the impact of arthralgia symptoms in other cohorts and other countries. To this end, we 
are currently developing a quantitative questionnaire to measure the type, severity and 
impact of symptoms in persons at risk of RA in order to explore commonality and 
prevalence of symptoms in people at risk of RA. 
 
In conclusion, anti-CCP antibody positive individuals with musculoskeletal symptoms that 
have been referred to a rheumatologist, who may or may not develop RA in the future, 
experience substantial physical and psychological impact of symptoms on their daily life. 
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Table 1: Participants in one of three focus group discussions 
Participant Tender joint 
count  
(0 to 53) 
Pain  
(VAS scale 0-
100) 
Duration of 
complaints before 
cohort entry 
Medication usage 
1 0 50 6 No 
2 0 15 25 No 
3 2 0 12 No 
4 2 15 9 HCQ and NSAIDs 
5 6 0 12 No 
6 6 71 24 No 
7 8 40 12 NSAIDs 
8 8 25 5 HCQ and NSAIDs 
9 6 49 22 No 
10 11 40 12 NSAIDs 
11 8 24 12 NSAIDs 
12 0 40 4 NSAIDs 
13 1 55 8 No 
14 0 54 8 NSAIDs 
15 0 3 18 No 
 
 
 
Table 2: Quotes supporting the themes regarding the impact of participants’ symptoms 
Physical impact 
Ph1.1 P11: ‘In the hands. Especially when closing buttons, I can’t close buttons.’ 
P12: ‘I just leave them closed [red: buttons], and just pull it over my head.’ 
Ph1.2 P2: ‘Like cleaning potatoes, I don’t do that anymore. Because I notice…and that 
frustrates me, so I buy clean potatoes’. 
Ph1.3 P3: ‘Well, opening a jar, opening the water faucet, taking something, ...’ 
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Ph1.4 P12: ‘I played the piano a lot and I can’t do that anymore, not as fast as I used to, 
especially not when I am having an attack, so those kind of things...’ 
Ph1.5 P5: ‘That you can’t make certain movements. One day, I wanted to rise from my chair 
and I just fell backwards, I couldn’t walk.’  
Ph1.6 P6: ‘The mobility. It can just surprise you, that you suddenly can’t do anything. With 
cooking, everything is clumsy.’  
P5: ‘Yes, and peeling potatoes’ 
Ph1.7 P7: ‘Just opening a bottle of Coke when you have friends over, then you have to ask 
someone to open it for you. That makes me very sad at my age’  [red: Lady is 46]  
Psychological impact 
Fear of future development of RA 
Psy2.1 P12: ‘That is what bothers me the most. That idea of: “Oh now I get it [referring to 
RA], now it starts”.’  
 P13: ‘Because it never lasts long, I know it will always subside. I think what troubles 
me the most is the hope it doesn’t get worse. If it remains like this, I can live with it.’ 
Psy2.2 P9: ‘I was referred to the rheumatologist, so yes, that fear that I could now be 
entering a phase of becoming a patient. That’s really uncomfortable.’ 
Psy2.3 P11: ‘Uncertainty about it becoming worse or not; if I knew this level could be 
stabilized, that this would be it, I would sign up for that immediately.’ 
Uncertainty 
Psy3.1 P14: ‘I always said I would never marry again, but last year I did. I am a wedding 
officer, so I feel warmly about marriage, but I thought no, I will not do that again. I 
have three kids, and no. And then I thought, yes, but this is a guy that will, if I end 
up in a wheelchair, I hope not but if I do, I am certain that he will push me around.’    
Mod: ‘And did that play a role?’ 
P14: ‘that has certainly played a role in my decision.’  
P15: ‘that is the certainty that gives you some air.’  
P14: ‘If I didn’t have this [red: arthralgia] I might not have married him, we would 
have just lived together.’ 
Psy3.2 P7: ‘Well, I have been honest with my boss. I told her, one moment it’s worse than 
the other moment. My colleagues know it as well. But I can imagine, I have that 
uncertainty as well, especially now and for the future, since the new generation is 
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coming. If they can hire a young person, without any complaints, then I’m the first to 
go.’ 
Psy3.3 P4: ‘I have a problem with that, that you think ‘what will happen’? I’m 59, alone for 4 
years, and then you start thinking...’ 
P5: ‘who will take care of me?’  
P7: ‘Yes, who takes care of me, that’s what I say. And then you think, my boss is 
trying to push me out as well, partly because of my symptoms, so…’   
P4: ‘uncertain future.’ 
Psy3.4 P12: ‘that is what is bothering me about these symptoms, every time you think, is it 
because of this?[red: development of RA] That is annoying, that uncertainty is very 
annoying for me.’ 
P13: ‘I recognise that, because two weeks ago I got a sudden pain in my wrist and 
then you start to think is it because of this, or is it just because I hit it? I really don’t 
know.’ 
P14: ‘It’s the fear as well.’  
P13: ‘It disappeared again so I was relieved, that it might not be those symptoms 
that are related to RA. Because that’s with everything you feel now, or when you drop 
something. You think “Oh no, now it starts”, yes I recognize that.’  
Psy3.5 P10: ‘If I know what it is, then something might be done, maybe, or at least… I really 
want to know what it is.’ 
Shame 
Psy4.1 P7: ‘You feel ashamed too. I don’t dare to drink anything in large company; yes I 
bring a bottle of water, that can’t do much harm[red: shame of dropping her drink]. 
And that annoys me. It is quite a burden.’ 
P6: ‘We are all rather young to be having such complaints, so that’s frustrating, and 
that makes me sad. I find that hard to cope with. Sometimes when I get out of bed in 
the morning and I am slower than usual getting ready for work, and when I enter the 
office reasonably on time they always say something like ‘good afternoon!’ I told 
them during a meeting recently that these remarks are hurtful to me. I understand 
it’s a joke, but it is hurtful. And I think that is your feeling as well, not even the 
shame, but because you are afraid people will say something about it, and that’s 
annoying for you.’ 
Frustration 
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Psy5.1 P6: ‘A big part of it is frustration, but I also notice it makes me very sad, because I 
think we are still so young. These are symptoms you would expect in much older 
people.’ 
Despair 
Psy6.1 P7: ‘Yes, just painful, swollen, really hurting. I couldn’t do a thing. And then you come 
there and that guy [rheumatology intern on duty] says it’s overburdening or an acute 
form of arthritis, but that’s it. You get a box with drugs and it should get better within 
24 hours. They don’t check the blood, nothing, and right after that you get another 
attack. Then I think, in God’s name where do I go with this kind of attack? Because 
you can’t do a thing. My husband was shocked, because I have relatively thin wrists, 
but they became twice the size and my hands too. You can’t do a thing, it’s so painful. 
The tears are running down your face, you walk, can’t sit still, because you don’t 
know how to put your hands. You walk around the room, not knowing what to do, you 
sit down again. It drove me crazy, I was bordering on a depression, if this takes any 
longer I will just throw myself off ... I will just quit. I thought if this is what awaits 
me, than it’s over, I don’t need that.’  
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